Latest news for MBIA (NYSE:MBI) Stock

MBIA

NADSAQ:INTC

nasdaq:aapl

NASDAQ:AMAT

NASDAQ:APOL

NASDAQ:INTC

NASDAQ:NVDA

NASDAQ:RIMM

nasdaq:shld

NYSE:AA

NYSE:AMD

NYSE:AXP

nyse:bby

NYSE:FCX

nyse:gm

NYSE:HAL

NYSE:HD

NYSE:HPQ

NYSE:JPM

NYSE:LEN

nyse:m

NYSE:MBI

NYSE:RIG

NYSE:RIO

NYSE:SVU

nyse:t

nyse:tif

NYSE:TLB

nyse:vz

Soaring Crude Nudges Markets Higher

Propped Up By Energy Stocks, Markets Cling to Green

Trading Ideas

RLAY

Relay Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Down -13.5%

JPMorgan shifted gears on <a href="https://www.benzinga.com/topic/mobility">air mobility stocks</a> Archer Aviation Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) and Joby Aviation Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>), downgrading them despite strong sector enthusiasm.
Analyst Bill Peterson adjusted Archer Aviation stock to a Neutral rating and Joby Aviation stock to Underweight, noting their significant market gains surged past what fundamentals justify.
<h1 class="wp-block-heading">Market Enthusiasm Outpaces Fundamentals</h1>
Peterson highlighted that Archer and Joby have outperformed the Clean Tech sector, gaining 145% and 86%, respectively, over the past six months. This rise correlates with speculative inflows and market movements aligned with Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Rocket Lab USA Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>). &#8220;These companies are trading as if regulatory hurdles have already been cleared,&#8221; Peterson stated, warning that elevated valuations could retreat as regulatory challenges persist.
Read Also: <a href="https://www.benzinga.com/tech/25/01/42905406/tesla-launches-refreshed-model-y-in-china-amid-rising-competition">Tesla Launches Refreshed Model Y In China Amid Rising Competition</a>
<h1 class="wp-block-heading">Certification Challenges Continue</h1>
Despite potential regulatory possibly easing under the upcoming Trump administration, ongoing safety testing and certification remain hurdles. Peterson sees <a href="https://www.benzinga.com/24/12/42464770/whats-going-on-with-archer-aviation-stock-today">Archer&#8217;s partnership with defense tech company Anduril</a> as promising but believes its immediate valuation upside is capped.
He assigned a $9 price target, reflecting incremental earnings potential from its defense ventures.
Similarly, while Joby&#8217;s leadership in for-credit testing and partnerships,<a href="https://www.benzinga.com/trading-ideas/movers/24/11/42169194/joby-gets-toyotas-500m-dollar-lift-evtol-pioneer-making-new-highs"> such as with </a><a href="https://www.benzinga.com/trading-ideas/movers/24/11/42169194/joby-gets-toyotas-500m-dollar-lift-evtol-pioneer-making-new-highs">Toyota Motor Corp</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TM#NYSE">TM</a>), indicate future growth, Peterson remains cautious.
The raised price target of $6 still implies downside risk due to certification uncertainties and market volatility.
<h1 class="wp-block-heading">Balancing Growth Potential, Risks</h1>
Peterson anticipates potential capital raises to fund commercialization efforts for both companies. 
&#8220;Investors must tread carefully,&#8221; he warned, suggesting that high short interest could lead to rapid price declines despite operational progress. 
As Archer and Joby push toward commercialization, the analyst sees significant long-term potential but remains wary of near-term risks tied to market enthusiasm outpacing operational milestones.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/tech/25/01/42909739/onvo-l60-delivers-big-for-nio-over-20000-vehicles-sold-in-first-100-days">Onvo L60 Delivers Big For Nio: Over 20,000 Vehicles Sold In First 100 Days</a></li>
</ul>
Photo: Courtesy Joby Aviation

Long Ideas

Downgrades

Analyst Ratings

Tech

ACHR

JOBY

RKLB

TSLA

eVTOL Market Soars Too High? Analyst Gives Archer, Joby Downgrades

Relay Therapeutics Shares Resume Trade

CHSN

Chanson International Shares Resume Trade

<a href="https://www.ft.com/content/fdd081b7-4ae3-4160-a246-a0afe1b86df2" title="https://www.ft.com/content/fdd081b7-4ae3-4160-a246-a0afe1b86df2">https://www.ft.com/content/fdd081b7-4ae3-4160-a246-a0afe1b86df2</a>

"Eli Lilly In Advanced Talks To Buy U.S. Cancer Biotech For Up To $2.5B; Scorpion's Drug Candidate Inhibits A Mutation That Is A Major Driver Of Breast, Gynaecological And Head And Neck Cancers" - Financial Times

Whales with a lot of money to spend have taken a noticeably bullish stance on YPF.
Looking at options history for YPF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YPF#NYSE">YPF</a>) we detected 13 trades.
If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish expectations and 38% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $560,033 and 10, calls, for a total amount of $788,909.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $30.0 to $60.0 for YPF over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for YPF's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of YPF's whale trades within a strike price range from $30.0 to $60.0 in the last 30 days. 
<h3>YPF 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736534732_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>YPF</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$7.7</td>
<td>$7.6</td>
<td>$7.7</td>
<td>$48.00</td>
<td>$308.0K</td>
<td>100</td>
<td>235</td>
</tr>
<tr>
<td>YPF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.65</td>
<td>$1.65</td>
<td>$1.65</td>
<td>$45.00</td>
<td>$206.9K</td>
<td>7.7K</td>
<td>1.2K</td>
</tr>
<tr>
<td>YPF</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>07/18/25</td>
<td>$7.8</td>
<td>$7.7</td>
<td>$7.7</td>
<td>$48.00</td>
<td>$180.9K</td>
<td>100</td>
<td>235</td>
</tr>
<tr>
<td>YPF</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.75</td>
<td>$1.5</td>
<td>$1.65</td>
<td>$45.00</td>
<td>$124.2K</td>
<td>7.7K</td>
<td>1.2K</td>
</tr>
<tr>
<td>YPF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$4.3</td>
<td>$4.2</td>
<td>$4.2</td>
<td>$55.00</td>
<td>$101.6K</td>
<td>648</td>
<td>250</td>
</tr>
</tbody>
</table>

<h3>About YPF</h3>
YPF SA is an Argentina-based integrated oil and gas company. It is engaged in operating a fully integrated oil and gas chain across the domestic upstream, downstream, and gas and power segments. The company's upstream operations consist of the exploration, development, and production of crude oil, natural gas, and LPG. Its downstream operations include the refining, marketing, transportation, and distribution of oil and a wide range of petroleum products, petroleum derivatives, petrochemicals, LPG, and bio-fuels. The company generates maximum revenue from the downstream segment.
After a thorough review of the options trading surrounding YPF, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>YPF's Current Market Status</h3>
<ul>
<li>With a trading volume of 2,182,876, the price of YPF is up by 0.66%, reaching $45.62.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 54 days from now.</li>
</ul>
<h3>What The Experts Say On YPF</h3>
Over the past month, 1 industry analysts have shared their insights on this stock, proposing an average target price of $59.5.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from JP Morgan has elevated its stance to Overweight, setting a new price target at $59. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest YPF options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

What the Options Market Tells Us About YPF

Investors with a lot of money to spend have taken a bullish stance on VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with VFC, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 10 uncommon options trades for VF.
This isn't normal.
The overall sentiment of these big-money traders is split between 70% bullish and 30%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $117,275, and 7 are calls, for a total amount of $446,341.
<h3>Projected Price Targets</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $10.0 and $25.0 for VF, spanning the last three months.
<h3>Insights into Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for VF options trades today is 11987.14 with a total volume of 26,411.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for VF's big money trades within a strike price range of $10.0 to $25.0 over the last 30 days.
<h3>VF Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736534728_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VFC</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.1</td>
<td>$1.07</td>
<td>$1.11</td>
<td>$22.50</td>
<td>$163.1K</td>
<td>35.3K</td>
<td>7.9K</td>
</tr>
<tr>
<td>VFC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.85</td>
<td>$2.85</td>
<td>$2.85</td>
<td>$20.00</td>
<td>$91.2K</td>
<td>23.1K</td>
<td>373</td>
</tr>
<tr>
<td>VFC</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$6.45</td>
<td>$5.8</td>
<td>$6.35</td>
<td>$20.00</td>
<td>$63.5K</td>
<td>3.5K</td>
<td>101</td>
</tr>
<tr>
<td>VFC</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$0.55</td>
<td>$0.47</td>
<td>$0.55</td>
<td>$21.00</td>
<td>$49.2K</td>
<td>1.4K</td>
<td>1.1K</td>
</tr>
<tr>
<td>VFC</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$3.55</td>
<td>$3.45</td>
<td>$3.55</td>
<td>$22.50</td>
<td>$42.2K</td>
<td>76</td>
<td>120</td>
</tr>
</tbody>
</table>

<h3>About VF</h3>
VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Altra, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. Tracing its roots to 1899, the company has evolved through many brand acquisitions and dispositions.
Having examined the options trading patterns of VF, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Present Market Standing of VF</h3>
<ul>
<li>Trading volume stands at 4,583,956, with VFC's price up by 5.8%, positioned at $22.79.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 19 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for VF, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

VF Options Trading: A Deep Dive into Market Sentiment

Financial giants have made a conspicuous bearish move on Tesla. Our analysis of options history for Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) revealed 504 unusual trades.
Delving into the details, we found 38% of traders were bullish, while 44% showed bearish tendencies. Out of all the trades we spotted, 236 were puts, with a value of $27,601,967, and 268 were calls, valued at $16,051,866.
<h3>Expected Price Movements</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $100.0 and $890.0 for Tesla, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Tesla options trades today is 5062.4 with a total volume of 8,254,798.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Tesla's big money trades within a strike price range of $100.0 to $890.0 over the last 30 days.
<h3>Tesla Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1736534723_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSLA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/10/25</td>
<td>$405.05</td>
<td>$403.45</td>
<td>$403.7</td>
<td>$800.00</td>
<td>$2.0M</td>
<td align="right">0</td>
<td align="right">50</td>
</tr>
<tr>
<td>TSLA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/10/25</td>
<td>$404.35</td>
<td>$401.95</td>
<td>$403.01</td>
<td>$800.00</td>
<td>$2.0M</td>
<td align="right">0</td>
<td align="right">250</td>
</tr>
<tr>
<td>TSLA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/10/25</td>
<td>$404.35</td>
<td>$401.95</td>
<td>$403.01</td>
<td>$800.00</td>
<td>$2.0M</td>
<td align="right">0</td>
<td align="right">150</td>
</tr>
<tr>
<td>TSLA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/10/25</td>
<td>$204.55</td>
<td>$202.3</td>
<td>$203.5</td>
<td>$600.00</td>
<td>$1.0M</td>
<td align="right">0</td>
<td align="right">50</td>
</tr>
<tr>
<td>TSLA</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/15/27</td>
<td>$180.8</td>
<td>$179.65</td>
<td>$180.27</td>
<td>$500.00</td>
<td>$162.2K</td>
<td align="right">480</td>
<td align="right">18</td>
</tr>
</tbody>
</table>

<h3>About Tesla</h3>
Tesla is a vertically integrated battery electric vehicle automaker and developer of autonomous driving software. The company has multiple vehicles in its fleet, which include luxury and midsize sedans, crossover SUVs, a light truck, and a semi truck. Tesla also plans to begin selling more affordable vehicles, a sports car, and a robotaxi. Global deliveries in 2024 were a little below 1.8 million vehicles. The company sells batteries for stationary storage for residential and commercial properties including utilities and solar panels and solar roofs for energy generation. Tesla also owns a fast-charging network.
<h3>Current Position of Tesla</h3>
<ul>
<li>Trading volume stands at 44,313,069, with TSLA's price up by 0.63%, positioned at $397.44.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 19 days.</li>
</ul>
<h3>Expert Opinions on Tesla</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $349.972.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Canaccord Genuity keeps a Buy rating on Tesla with a target price of $404. 
&#x2A; An analyst from Truist Securities has decided to maintain their Hold rating on Tesla, which currently sits at a price target of $351. 
&#x2A; An analyst from B of A Securities has revised its rating downward to Neutral, adjusting the price target to $490. 
&#x2A; An analyst from Baird has decided to maintain their Outperform rating on Tesla, which currently sits at a price target of $480. 
&#x2A; An analyst from GLJ Research has revised its rating downward to Sell, adjusting the price target to $24. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Tesla, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Unpacking the Latest Options Trading Trends in Tesla

Chanson International Shares Halted On Circuit Breaker To The Downside, Stock Now Down -18.8%

Fashion company Capri Holdings Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPRI#NYSE">CPRI</a>) shares are trading higher on Friday. Italian luxury fashion brand Prada is said to be among the potential buyers exploring a bid for Versace, the renowned fashion group currently <a href="https://www.benzinga.com/25/01/42824409/sentiment-for-capri-holdings-has-turned-too-negative-this-analyst-notes-3-ways-to-win">up for sale by Capri.</a>
Prada is working with Citigroup Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>) to assess the feasibility of a possible acquisition, according to a report from Reuters.
The move comes after the Federal Trade Commission has launched a lawsuit to halt <a href="https://www.benzinga.com/markets/equities/24/04/38382351/ftc-files-lawsuit-to-block-8-5b-merger-of-coach-and-versace-handbag-makers">the $8.5 billion acquisition</a> of Capri by Tapestry Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>). Both companies decided to mutually end their merger agreement, citing uncertainties in the legal process and the expectation that it would not be resolved by the <a href="https://www.benzinga.com/news/buybacks/24/11/41971497/tapestry-and-capri-call-off-8-5b-deal-amid-legal-hurdles">Feb. 10, 2025 deadline</a>.
Also Read: <a href="https://www.benzinga.com/25/01/42908403/macys-shuts-down-66-locations-to-boost-profitability">Macy&#8217;s Shuts Down 66 Locations As Part Of New Chapter Strategy</a>
Since then Capri has been exploring potential buyers for its Versace and Jimmy Choo brands and was said to have created a data room containing confidential details about the businesses for prospective buyers, with the goal of gauging interest <a href="https://www.benzinga.com/24/12/42513221/capri-holdings-stock-climbs-on-report-of-potential-sale-of-versace-jimmy-choo">before the holiday season</a>.
Capri is the parent company for fashion brands like Versace, Jimmy Choo, and Michael Kors.
The company reported a 16.4% decline in its second-quarter FY25 revenue with Versace&#8217;s decreasing 28.2%, impacted by softening global demand for <a href="https://www.capriholdings.com/news-releases/news-releases-details/2024/Capri-Holdings-Limited-Announces-Second-Quarter-Fiscal-2025-Results-b3d8ee77e/default.aspx">fashion luxury goods</a>.
Prada, on the other hand, posted a revenue of €3.829 billion for the nine months ending on <a href="https://www.pradagroup.com/content/dam/pradagroup/documents/investors/9M-2024/24.10.30_Prada_Group_Q3-24_Results_Press_Release.pdf" target="_blank" rel="noopener">Sep. 30, 2024, an 18% increase</a>.
Price Action: CPRI shares were up 9.5% at $23.56 at last check Friday.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/01/42913319/beer-maker-constellation-brands-q3-sales-hit-by-subdued-spending-stock-slides">Beer Maker Constellation Brands&#8217; Q3 Sales Hit By Subdued Spending</a></li>
</ul>
Photo: Giorgio Borelli/Shutterstock.com

News

Movers

General

CPRI

Capri's Stock Rises As Prada Considers Potential Acquisition Of Versace

Relay Therapeutics Shares Halted On Circuit Breaker To The Downside, Stock Now Up 4.55%

Citigroup analyst Christopher Allen maintains Interactive Brokers Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IBKR#NASDAQ">IBKR</a>) with a Buy and raises the price target from $180 to $220.

Price Target

IBKR

Citigroup Maintains Buy on Interactive Brokers Gr, Raises Price Target to $220

Relay Therapeutics Shares Resume Trade Following Circuit Breaker Halt

Citigroup analyst Christopher Allen maintains LPL Finl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LPLA#NASDAQ">LPLA</a>) with a Buy and raises the price target from $310 to $385.

LPLA

Citigroup Maintains Buy on LPL Finl Hldgs, Raises Price Target to $385

On Friday, Dyne Therapeutics, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DYN#NASDAQ">DYN</a>) revealed new data from its ongoing Phase 1/2 ACHIEVE trial of DYNE-101 in patients with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/g42908297/dyne-therapeutics-reports-new-clinical-data-showing-compelling-impact-on-multiple-measures-of-myot" rel="noreferrer noopener">myotonic dystrophy type 1 (DM1)</a>.
Dyne plans to begin a global Registrational Expansion Cohort with the potential to support a submission for U.S. Accelerated Approval based on biomarker and functional data in H1 2026.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40692261/muscle-disease-drug-developer-dyne-therapeutics-stock-plunges-after-updated-data-from-duchenne-mu" rel="noreferrer noopener">Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy</a>
Dyne reported efficacy data from adult DM1 patients enrolled in the randomized, placebo-controlled MAD portion of the DYNE-101 ACHIEVE trial, including data from the 6.8 mg/kg Q8W cohort (n=8) at up to 6 months.
At the 6.8 mg/kg Q8W dose, DYNE-101 resulted in significant splicing correction at 3 months compared to baseline, which was associated with progress in multiple functional endpoints, beginning at 3 months and continuing at 6 months.
<ul>
<li>Analysis of muscle biopsy data for the 6.8 mg/kg Q8W cohort showed a substantial knockdown of Drug Metabolism and Pharmacokinetics (DMPK) (DYNE-101 molecular target) RNA levels. Splicing correction at 3 months for the 6.8 mg/kg Q8W cohort was robust. It was associated with improvement in multiple functional endpoints, supporting CASI-22 at 3 months as a surrogate endpoint for potential U.S. Accelerated Approval.</li>
<li>Early and sustained improvement in myotonia as measured by video hand opening time (vHOT) was seen in the 6.8 mg/kg Q8W cohort and at low doses with modest splicing correction, deepening with more time on the drug.</li>
<li>Functional measures showed early and sustained clinical benefit at the 6.8 mg/kg Q8W dose.</li>
</ul>
Dyne also reported safety and tolerability data from 56 patients. Most of the treatment-emergent adverse events were mild or moderate, and no related serious treatment-emergent adverse events have been identified.
Based on previous dialogue with the FDA&#8217;s Center for Drug Evaluation and Research division, Dyne continues to pursue accelerated approval in the U.S. based on splicing as a surrogate endpoint.
Dyne anticipates completing enrollment in the Registrational Expansion Cohort in mid-2025 and submitting for U.S. Accelerated Approval in H1 2026.
Price Action: DYN stock is down 35.3% at $14.91 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/01/42915528/td-synnex-shares-delivers-earnings-beat-and-boosts-dividend-by-10" target="_blank" rel="noreferrer noopener">TD SYNNEX Delivers Strong Q4, Raises Dividend Amid IT Growth Momentum; Stock Gains</a></li>
</ul>
Image via Shutterstock.

Biotech

Equities

Health Care

Why Is Neuromuscular-Focused Dyne Therapeutics Stock Trading Lower On Friday?

Citigroup analyst Christopher Allen maintains Raymond James Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>) with a Neutral and raises the price target from $145 to $170.

Citigroup Maintains Neutral on Raymond James Finl, Raises Price Target to $170

Citigroup analyst Christopher Allen maintains Robinhood Markets (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) with a Neutral and raises the price target from $25 to $45.

HOOD

Citigroup Maintains Neutral on Robinhood Markets, Raises Price Target to $45

Citigroup analyst Christopher Allen maintains Stifel Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SF#NYSE">SF</a>) with a Neutral and raises the price target from $110 to $115.

Citigroup Maintains Neutral on Stifel Financial, Raises Price Target to $115

Citigroup analyst Christopher Allen maintains Nasdaq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDAQ#NASDAQ">NDAQ</a>) with a Neutral and raises the price target from $78 to $84.

NDAQ

Citigroup Maintains Neutral on Nasdaq, Raises Price Target to $84

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the real estate sector.
<h3 class="wp-block-heading">Medical Properties Trust, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPW#NYSE">MPW</a>)</h3>
<ul>
<li>Dividend Yield: 8.54%</li>
<li>Truist Securities analyst Michael Lewis maintained a Hold rating and cut the price target from $6 to $4 on Dec. 19, 2024. This analyst has an accuracy rate of 69%.</li>
<li>RBC Capital analyst Michael Carroll downgraded the stock from Outperform to Sector Perform with a price target of $5 on May 14, 2024. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: On Nov.7, Medical Properties Trust reported worse-than-expected third-quarter financial results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1">latest MPW news.</a> </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/8356f98b-748a-4a66-8e7b-6e4f0dc6db31" alt="" style="width:606px;height:auto" /></a></figure>
<h3 class="wp-block-heading">EPR Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPR#NYSE">EPR</a>)</h3>
<ul>
<li>Dividend Yield: 7.74%</li>
<li>JP Morgan analyst Anthony Paolone maintained an Overweight rating and raised the price target from $48 to $51 on Sept. 9, 2024. This analyst has an accuracy rate of 64%.</li>
<li>Truist Securities analyst Ki Bin Kim maintained a Hold rating and boosted the price target from $44 to $46 on Aug. 16, 2024. This analyst has an accuracy rate of 67%.</li>
<li>Recent News: On Oct. 30, EPR Props posted better-than-expected quarterly results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1">latest EPR new</a>s.</li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/25fde8ab-3a45-4b71-980a-0efe0c0d9950" alt="" style="width:631px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Omega Healthcare Investors, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>)</h3>
<ul>
<li>Dividend Yield: 7.39%</li>
<li>RBC Capital analyst Michael Carroll maintained a Sector Perform rating and raised the price target from $39 to $43 on Nov. 11, 2024. This analyst has an accuracy rate of 61%.</li>
<li>Wells Fargo analyst Connor Siversky assumed an Overweight rating and increased the price target from $40 to $43 on Oct. 1, 2024. This analyst has an accuracy rate of 63%.</li>
<li>Recent News: On Jan. 6, Omega Healthcare Investors named Matthew Gourmand as President.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1">OHI news</a>.</li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent011025&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="893" height="827" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10133010/image-64.png" alt="" class="wp-image-728777" style="width:563px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10133010/image-64.png 893w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10133010/image-64-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/01/10133010/image-64-768x711.png 768w" sizes="(max-width: 893px) 100vw, 893px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/01/42917071/top-2-health-care-stocks-that-are-ticking-portfolio-bombs-2">Top 2 Health Care Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

Dividends

Wall Street's Most Accurate Analysts Weigh In On 3 Real Estate Stocks With Over 7% Dividend Yields

Keefe, Bruyette & Woods

Roth MKM

Compass Point

Fueled by a buying binge in the energy sector amid $91-a-barrel oil, Wall Street reached the finish line on Tuesday with modest gains, putting a stop to the Dow's three-day slump.

Wall Street ticked modestly higher Tuesday afternoon as energy stocks rally around $90-a-barrel oil prices.

Comments

MBIA

News

Latest news for MBIA (NYSE:MBI) Stock

Tuesday, January 11, 2011

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga